264W 94
|
|
|
- CAS号:
- 178961-24-5
- 英文名:
- 264W 94
- 英文别名:
- 264W 94;264W94,264W-94;1,4-Benzothiazepine, 3-butyl-3-ethyl-2,3,4,5-tetrahydro-7,8-dimethoxy-5-phenyl-, 1,1-dioxide, (3R,5R)-rel-
- 中文名:
- 264W 94
- 中文别名:
- 化合物 T10090
- CBNumber:
- CB91370970
- 分子式:
- C23H31NO4S
- 分子量:
- 417.56
- MOL File:
- 178961-24-5.mol
|
|
|
264W 94化学性质
-
沸点:
-
553.0±50.0 °C(Predicted)
-
|
-
密度:
-
1.112±0.06 g/cm3(Predicted)
-
|
-
酸度系数(pKa):
-
5.81±0.60(Predicted)
-
|
264W 94性质、用途与生产工艺
264W94 是有效的回肠胆汁酸转运蛋白 (IBAT) 抑制剂，是新型降胆固醇药。264W94 具有 CYP7A1 诱导作用和抗血脂作用。
264W94 (0, 0.1, 0.25, 0.5 μM) inhibits human IBAT-specific transport of 5 μM TC by 14% to 75% in a concentration-dependent manner with IC
50
of 0.25 μM in CHO-hIBAT cells.
264W94 (orally; 0.03-1.0 mg/kg; twice a day for 3.5 days) dose-dependently attenuates diet-induced increases in serum LDL+VLDL-C, as well as the decrease in HDL-C.
264W94 (orally; 0.003, 0.01, 0.03, 0.1 mg/kg; twice a day for 2 days) increases fecal excretion of
75
SeHCAT in a dose-dependent manner.
264W94 (0.001, 0.01, 0.1, 1, and 10 mg/kg; twice a day for 2 weeks) reduces dose-dependently plasma glucose in male ZDF (ZDF/GmiCrl-
fa/fa
) rats. Treatment of 264W94 prevents the decline of insulin dose-dependently without an increase in proinsulin levels.
|
Animal Model:
|
Male Sprague Dawley rats (CD, Charles River, 270-310 gm)
|
|
Dosage:
|
0.03, 0.1, 0.3, 1.0 mg/kg
|
|
Administration:
|
Orally; twice a day (9:00 am and 3:30 pm) for 3.5 days
|
|
Result:
|
Dose-dependently attenuated diet-induced increases in serum LDL+VLDL-C, as well as the decrease in HDL-C.
|
264W 94
上下游产品信息
上游原料
下游产品
178961-24-5, 264W 94 相关搜索:
- 化合物 T10090
- 178961-24-5
- 1,4-Benzothiazepine, 3-butyl-3-ethyl-2,3,4,5-tetrahydro-7,8-dimethoxy-5-phenyl-, 1,1-dioxide, (3R,5R)-rel-
- 264W94,264W-94
- 264W 94